Posted by Michael Wonder on 18 Jan 2023
HUTCHMED announces agreement with NHSA for inclusion of Orpathys in the National Reimbursement Drug List in China
18 January 2023 - HUTCHMED China today announces, following negotiations with the China National Healthcare Security Administration, Orpathys (savolitinib) has been included in the updated National Reimbursement Drug List for the treatment of locally advanced or metastatic non-small cell lung cancer adult patients with MET exon 14 skipping alterations who have progressed after or unable to tolerate platinum-based chemotherapy.
The updated National Reimbursement Drug List will take effect from 1 March 2023.
